// App-Quantinova.ai

: SHOULD THE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA WITH MATURE PHENOTYPE AND KMT2A REARRANGEMENTS BE CONSIDERED AS A NEW ENTITY?

Researchers

Presenter

  • Gloria Hidalgo Gomez

Principal Investigators

  • Maria Gabarros

  • Adoracin Blanco

  • Brbara Tazn

  • Carlos Palacio

  • Laura Gallur

  • Noemi Martnez

  • Montse Aznar

  • Lidia Altimiras

  • Jose Luis Dapena

  • Margarita Ortega

Medical Centers

  • Experimental Hematology Group,Vall d'Hebron Institute of Oncology (VHIO),Barcelona,Spain;Integrated Diagnosis Unit, Hematology Service,Vall d'Hebron University Hospital,Barcelona,Spain

  • Integrated Diagnosis Unit, Hematology Service,Vall d'Hebron University Hospital,Barcelona,Spain

  • Pediatric Oncology and Hematology Service,Vall d'Hebron University Hospital,Barcelona,Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Histone-lysine N-methyltransferase 2A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved